US 12,070,476 B2
Engineered parasites for delivering protein to the central nervous system (CNS)
Oded Rechavi, Tel-Aviv (IL); Shahar Bracha, Tel-Aviv (IL); and Lilach Sheiner, Glasgow (GB)
Assigned to Ramot at Tel-Aviv University Ltd., Tel-Aviv (IL); and The University Court of the University of Glasgow, Glasgow (GB)
Filed by Ramot at Tel-Aviv University Ltd., Tel-Aviv (IL); and The University Court of the University of Glasgow, Glasgow (GB)
Filed on Jan. 26, 2022, as Appl. No. 17/584,508.
Application 17/584,508 is a division of application No. 16/313,060, granted, now 11,260,081, previously published as PCT/IL2017/050731, filed on Jun. 29, 2017.
Claims priority of provisional application 62/355,898, filed on Jun. 29, 2016.
Prior Publication US 2022/0160790 A1, May 26, 2022
Int. Cl. A61K 35/68 (2006.01); C07K 14/45 (2006.01); C12N 9/00 (2006.01); C12N 15/65 (2006.01); C12N 15/79 (2006.01)
CPC A61K 35/68 (2013.01) [C07K 14/45 (2013.01); C12N 9/93 (2013.01); C12N 15/65 (2013.01); C12N 15/79 (2013.01); C07K 2319/10 (2013.01); C12Y 603/05005 (2013.01)] 18 Claims
 
1. A nucleic acid construct comprising a heterologous polynucleotide comprising a first nucleic acid sequence encoding a Toxoplasma secreted protein in frame fused upstream to a second nucleic acid sequence encoding a pharmaceutical polypeptide, wherein said Toxoplasma secreted protein is secreted to a host cell when infected by the Toxoplasma, wherein said heterologous polynucleotide is operably linked to a promoter for directing transcription of said heterologous polynucleotide in a Toxoplasma, wherein said promoter is selected from the group consisting of: a constitutive promoter, an inducible promoter, a latent period-specific promoter, and a Toxoplasma endogenous promoter with the proviso that said promoter is not a Toxofilin promoter.